2. Metabolic Enzyme/Protease NF-κB Apoptosis Autophagy Immunology/Inflammation
  3. Proteasome NF-κB Apoptosis Autophagy TREM receptor
  4. Bortezomib

Bortezomib  (Synonyms: PS-341; LDP-341; NSC 681239)

Cat. No.: HY-10227 Purity: 99.80%
COA
SDS
Handling Instructions Technical Support

Bortézomib (PS-341) est un protéasome inhibiteur réversible et sélectif, et inhibe puissamment le protéasome 20S (Ki=0,6 nM) en ciblant sur un résidu de thréonine. Bortézomib perturbe le cycle cellulaire, induit l'apoptose et inhibe NF-κB. Bortézomib est le premier inhibiteur thérapeutique du protéasome utilisé chez l'homme. L'activité anticancéreuse.

Bortezomib (PS-341) ist ein reversibler und selektiver proteasome-Inhibitor und hemmt das 20S proteasome (Ki=0.6 nM) stark, indem es auf einen Threonin-Rest abzielt. Bortezomib stört den Zellzyklus, induziert Apoptose und hemmt NF-κB. Anti-Krebs-Aktivität.

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).

For research use only. We do not sell to patients.

CAS No. : 179324-69-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 248 publication(s) in Google Scholar

Other Forms of Bortezomib:

Bortezomib Related Antibodies

Top Publications Citing Use of Products

248 Publications Citing Use of MCE Bortezomib

IF
WB
Cell Proliferation/Viability Assay

    Bortezomib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 Apr;479(4):843-857.  [Abstract]

    Bortezomib (BTZ; 5, 10, 20 nM; 48 h) increases the expression level of γH2AX in RPMI-8226 and U266 cells.

    Bortezomib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 Apr;479(4):843-857.  [Abstract]

    Bortezomib (BTZ; 10 nM; 48 h) significantly enhances the cell death of RPMI-8226.

    Bortezomib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jun 15;25(12):3630-3642.  [Abstract]

    H1975 cells treated with 5 μmol/L MTI-31 alone or in combination with 10 μmol/L CQ or 0.01 μmol/L PS-341.

    Bortezomib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604.  [Abstract]

    The accumulated SQSTM1 by either proteasome inhibitors or PPI was sensitive to autophagy mediated degradation. AGS cells were pretreated with 25 and 50nM bortezomib for 1h, and then incubated with 500nM torin 1 for 24h (g). After pretreatment with PPI for 24h in pH 7.4 or pH 6.5 condition, rapamycin (1μM) or torin 1 (500 nM) was added for another 24h (h). The protein level of SQSTM1 was measured by western blot analysis (g, h).

    Bortezomib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604.  [Abstract]

    Different concentrations of two classical proteasome inhibitors Bortezomib and MG132 are added. AGS cells are either untreated or treated with Bortezomib (25 nM) or MG132 (0.1 μM) for 24 h in the absence or presence of baf A1 (100 nM).

    Bortezomib purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430.  [Abstract]

    Kelly cells are treated with increasing concentrations of Thalidomide and co-treated with 5 μM Bortezomib, 5 μM MLN4924, 0.5 μM MLN7243, or DMSO as a control. Following 24 h incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.

    Bortezomib purchased from MedChemExpress. Usage Cited in: BMC Cancer. 2018 Oct 11;18(1):971.  [Abstract]

    The reduction of MAGEC2 protein level in TRIM28-knockdown A375 cells can be inhibited by treatment with both MG132 and PS-341, and similar result is also observed in Hs 695 T cells.

    Bortezomib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2017 Nov 15:815:147-155.  [Abstract]

    Shown are GFPu fluorescent images of the GFPu-HEK293 cells treated with CuSO4 (Cu, 20 μM), HK (20 μM), HK-Cu (HC, 20 μM), or Velcade (Vel, 100 nM).

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    View All TREM receptor Isoform Specific Products:

    View All Isoforms
    TREM-1 TREM-2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM)[1][2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs)[7].

    IC50 & Target

    Ki: 0.6 nM (20S proteasome)[1]
    Cellular Effect
    Cell Line Type Value Description References
    5TGM1 IC50
    6.78 1
    Compound: PS-341, Bortezomib
    Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay
    Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay
    		[PMID: 24119559]
    5TGM1 IC50
    6.78 1
    Compound: PS-341, Bortezomib
    Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay
    Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay
    		[PMID: 24119559]
    DLD-1 IC50
    0.2 1
    Compound: Bortezomib, Velcade, PS-341
    Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis
    Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis
    		[PMID: 22206869]
    A549 IC50
    9.318 3
    Compound: Bortezomib
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    A2780 IC50
    28.9 1
    Compound: Bortezomib
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    786-0 GI50
    1.44 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human 786-0 cells
    Growth inhibition of human 786-0 cells
    		[PMID: 24946214]
    A-431 IC50
    28.2 1
    Compound: Bortezomib
    Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    A-431 IC50
    28.2 1
    Compound: Bortezomib
    Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    RPMI-8226 GI50
    0.23 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human RPMI8226 cells
    Growth inhibition of human RPMI8226 cells
    		[PMID: 24946214]
    A549 IC50
    13.9 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    A2780 IC50
    1.7 1
    Compound: 1, bortezomib
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    		[PMID: 18247547]
    A549 IC50
    2.14 3
    Compound: Bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    A549 IC50
    0.62 3
    Compound: Bortezomib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    A549 IC50
    2.14 3
    Compound: Bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    A2780 IC50
    28.9 1
    Compound: Bortezomib
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    A498 GI50
    0.48 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human A498 cells
    Growth inhibition of human A498 cells
    		[PMID: 24946214]
    A549 IC50
    2.5 1
    Compound: Bortezomib
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    CCRF-CEM GI50
    0.35 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human CCRF-CEM cells
    Growth inhibition of human CCRF-CEM cells
    		[PMID: 24946214]
    A549 GI50
    3.09 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human A549/ATCC cells
    Growth inhibition of human A549/ATCC cells
    		[PMID: 24946214]
    A549 IC50
    2135.73 1
    Compound: PS-341
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    A549 IC50
    0.62 3
    Compound: Bortezomib
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    A549 IC50
    255 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    A549 IC50
    6.7 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    A549 IC50
    13.9 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    A549 IC50
    9.318 3
    Compound: Bortezomib
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    A549 IC50
    2.14 3
    Compound: Bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    A549 IC50
    2.5 1
    Compound: Bortezomib
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    A549 IC50
    92 1
    Compound: BTZ
    Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay
    Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay
    		[PMID: 28191850]
    ARH-77 IC50
    6.07 1
    Compound: Bortezomib
    Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay
    Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    MOLT-4 GI50
    0.51 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MOLT4 cells
    Growth inhibition of human MOLT4 cells
    		[PMID: 24946214]
    A549 IC50
    2135.73 1
    Compound: PS-341
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    ARH-77 IC50
    9.57 1
    Compound: Bortezomib
    Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    A549 IC50
    255 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    BEL-7404 tumor cell line IC50
    25.04 1
    Compound: PS-341
    Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    A549 IC50
    6.7 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    A549 IC50
    9.318 3
    Compound: Bortezomib
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    MCF7 GI50
    0.55 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MCF7 cells
    Growth inhibition of human MCF7 cells
    		[PMID: 24946214]
    BGC-823 IC50
    2890 1
    Compound: Bortezomib
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    BGC-823 IC50
    880 1
    Compound: bortezomib
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    A549 IC50
    92 1
    Compound: BTZ
    Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay
    Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay
    		[PMID: 28191850]
    BXPC-3 IC50
    11.8 1
    Compound: Bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    ACHN GI50
    0.79 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human ACHN cells
    Growth inhibition of human ACHN cells
    		[PMID: 24946214]
    BXPC-3 IC50
    16.2 1
    Compound: bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    BXPC-3 IC50
    19.4 1
    Compound: bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    ARH-77 IC50
    6.07 1
    Compound: Bortezomib
    Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay
    Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    Calu-6 IC50
    3.9 1
    Compound: Bortezomib
    Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay
    Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay
    		10.1039/C2MD20060K
    ARH-77 IC50
    9.57 1
    Compound: Bortezomib
    Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    HCT-116 GI50
    0.6 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HCT116 cells
    Growth inhibition of human HCT116 cells
    		[PMID: 24946214]
    CCRF-CEM GI50
    0.001 3
    Compound: Bortezomib
    Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    CCRF-CEM IC50
    11 1
    Compound: Bortezomib
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    DLD-1 IC50
    0.0002 3
    Compound: Bortezomib, Velcade, PS-341
    Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis
    Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis
    		[PMID: 22206869]
    BGC-823 IC50
    2890 1
    Compound: Bortezomib
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    BGC-823 IC50
    880 1
    Compound: bortezomib
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    DLD-1 IC50
    0.0009 3
    Compound: Bortezomib, Velcade, PS-341
    Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis
    Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis
    		[PMID: 22206869]
    GES1 IC50
    12.6 1
    Compound: PS-341
    Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    BT-549 GI50
    0.55 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human BT549 cells
    Growth inhibition of human BT549 cells
    		[PMID: 24946214]
    HCT-116 IC50
    0.001 3
    Compound: Bortezomib
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    BXPC-3 IC50
    11.8 1
    Compound: Bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    HCT-116 IC50
    0.01 3
    Compound: bortezomib
    Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 23547757]
    BXPC-3 IC50
    16.2 1
    Compound: bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    HCT-116 IC50
    1.4 1
    Compound: PS-341
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    BXPC-3 IC50
    19.4 1
    Compound: bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    DLD-1 IC50
    0.9 1
    Compound: Bortezomib, Velcade, PS-341
    Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis
    Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis
    		[PMID: 22206869]
    HCT-116 IC50
    27 1
    Compound: Bortezomib
    Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    CAKI-1 GI50
    0.66 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human CAKI-1 cells
    Growth inhibition of human CAKI-1 cells
    		[PMID: 24946214]
    HEK293 IC50
    0.014 3
    Compound: PS-341
    Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay
    Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay
    		[PMID: 21044847]
    CAL-27 IC50
    4.73 3
    Compound: BTZ
    Antiproliferative activity against human CAL-27 cells overexpressing HDAC4 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human CAL-27 cells overexpressing HDAC4 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37979441]
    HT-29 GI50
    0.95 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HT-29 cells
    Growth inhibition of human HT-29 cells
    		[PMID: 24946214]
    HEK293 IC50
    10 1
    Compound: 1, bortezomib
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay
    		[PMID: 20875739]
    CAL-27 IC50
    7.6 3
    Compound: BTZ
    Antiproliferative activity against human CAL-27 cells without HDAC4 expression assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human CAL-27 cells without HDAC4 expression assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37979441]
    HEK293 IC50
    27 1
    Compound: 1a, Bortezomib
    Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader
    Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader
    		[PMID: 21634429]
    CCRF-CEM GI50
    0.001 3
    Compound: Bortezomib
    Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    HEK293 CC50
    347 1
    Compound: 1a, Bortezomib
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    		[PMID: 21634429]
    NCI-H23 GI50
    1 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H23 cells
    Growth inhibition of human NCI-H23 cells
    		[PMID: 24946214]
    CCRF-CEM GI50
    0.35 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human CCRF-CEM cells
    Growth inhibition of human CCRF-CEM cells
    		[PMID: 24946214]
    HEK293 IC50
    9.7 1
    Compound: Bortezomib
    Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control
    Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control
    		10.1039/C2MD20060K
    CCRF-CEM IC50
    11 1
    Compound: Bortezomib
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    HEK-293T IC50
    12 1
    Compound: BTZ
    Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay
    Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay
    		[PMID: 28191850]
    HeLa IC50
    > 200 1
    Compound: Btz
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    COLO 205 GI50
    1.23 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human COLO205 cells
    Growth inhibition of human COLO205 cells
    		[PMID: 24946214]
    HeLa IC50
    0.02 3
    Compound: PS-341
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19428245]
    HeLa GI50
    168.1 3
    Compound: BTZ; Product S4
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32031798]
    Calu-6 IC50
    3.9 1
    Compound: Bortezomib
    Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay
    Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay
    		10.1039/C2MD20060K
    CCRF-CEM GI50
    0.001 3
    Compound: Bortezomib
    Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    HeLa IC50
    20 1
    Compound: Btz
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    HeLa IC50
    92 1
    Compound: bortezomib
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    K562 GI50
    1.17 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human K562 cells
    Growth inhibition of human K562 cells
    		[PMID: 24946214]
    HepG2 EC50
    0.01 3
    Compound: Bortezomib
    Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay
    Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 29800827]
    DLD-1 IC50
    0.0002 3
    Compound: Bortezomib, Velcade, PS-341
    Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis
    Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis
    		[PMID: 22206869]
    HepG2 IC50
    1.61 1
    Compound: PS-341
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    DLD-1 IC50
    0.0009 3
    Compound: Bortezomib, Velcade, PS-341
    Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis
    Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis
    		[PMID: 22206869]
    DU-145 GI50
    1.7 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human DU145 cells
    Growth inhibition of human DU145 cells
    		[PMID: 24946214]
    HepG2 GI50
    100.6 3
    Compound: BTZ; Product S4
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32031798]
    MDA-MB-231 GI50
    1.26 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MDA-MB-231 cells
    Growth inhibition of human MDA-MB-231 cells
    		[PMID: 24946214]
    HepG2 IC50
    25.2 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    EA.hy 926 IC50
    0.09 3
    Compound: Bortezomib
    Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    HCT-116 IC50
    1.4 1
    Compound: PS-341
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HepG2 IC50
    37.5 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    EKVX GI50
    3.02 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human EKVX cells
    Growth inhibition of human EKVX cells
    		[PMID: 24946214]
    RPMI-8226 IC50
    1.43 1
    Compound: PS-341
    Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HepG2 IC50
    7.5 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    HET-1A IC50
    25.6 1
    Compound: PS-341
    Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    GES1 IC50
    12.6 1
    Compound: PS-341
    Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HL-60 ED50
    0.0025 3
    Compound: Bortezomib
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay
    		[PMID: 21973101]
    HCC 2998 GI50
    0.6 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HCC2998 cells
    Growth inhibition of human HCC2998 cells
    		[PMID: 24946214]
    HL-60 IC50
    0.008 3
    Compound: Bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    HL-60 ED50
    2.5 1
    Compound: bortezomib
    Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins
    Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins
    		[PMID: 19422206]
    HL-60 IC50
    3.2 1
    Compound: Bortezomib
    Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    HL-60 IC50
    3.5 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HCT-116 GI50
    0.6 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HCT116 cells
    Growth inhibition of human HCT116 cells
    		[PMID: 24946214]
    HepG2 IC50
    1.61 1
    Compound: PS-341
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HCT-116 IC50
    0.001 3
    Compound: Bortezomib
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    SK-OV-3 IC50
    1.62 1
    Compound: PS-341
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HL-60 IC50
    5.5 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    HL-60 IC50
    6.9 1
    Compound: Bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    HCT-116 IC50
    0.01 3
    Compound: bortezomib
    Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 23547757]
    A2780 IC50
    1.7 1
    Compound: 1, bortezomib
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    		[PMID: 18247547]
    HL-60 IC50
    7.1 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    HCT-116 IC50
    1.4 1
    Compound: PS-341
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HL-60 IC50
    7.6 1
    Compound: PS-341
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HCT-116 IC50
    27 1
    Compound: Bortezomib
    Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    HT-29 ED50
    > 20 3
    Compound: Bortezomib
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    		[PMID: 21973101]
    HCT-116 IC50
    5 1
    Compound: bortezomib
    Inhibition of human HCT116 cell growth
    Inhibition of human HCT116 cell growth
    		[PMID: 24524217]
    HT-29 IC50
    3.2 1
    Compound: Btz
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    HUVEC IC50
    11.2 1
    Compound: PS-341
    Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HCT-15 GI50
    1.51 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HCT15 cells
    Growth inhibition of human HCT15 cells
    		[PMID: 24946214]
    K562 GI50
    0.007 3
    Compound: Bortezomib
    Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    HEK-293T IC50
    12 1
    Compound: BTZ
    Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay
    Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay
    		[PMID: 28191850]
    KB IC50
    59.5 1
    Compound: bortezomib
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    KM3/BTZ IC50
    226 1
    Compound: PS-341
    Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HEK293 CC50
    347 1
    Compound: 1a, Bortezomib
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    		[PMID: 21634429]
    L02 IC50
    55.5 1
    Compound: PS-341
    Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    U-266 IC50
    2.45 1
    Compound: bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    HEK293 IC50
    0.014 3
    Compound: PS-341
    Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay
    Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay
    		[PMID: 21044847]
    MCF7 IC50
    0.025 3
    Compound: Bz
    Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
    Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
    		[PMID: 28557430]
    HEK293 IC50
    10 1
    Compound: 1, bortezomib
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay
    		[PMID: 20875739]
    A549 IC50
    2.5 1
    Compound: Bortezomib
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    MCF7 IC50
    18.37 3
    Compound: Bortezomib
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    HEK293 IC50
    14 3
    Compound: Bortezomib
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition
    		[PMID: 33333398]
    HL-60 ED50
    2.5 1
    Compound: bortezomib
    Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins
    Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins
    		[PMID: 19422206]
    MDA-MB-231 IC50
    0.003 3
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MM1.S IC50
    2.5 1
    Compound: BTZ
    Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    		[PMID: 34445874]
    HEK293 IC50
    27 1
    Compound: 1a, Bortezomib
    Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader
    Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader
    		[PMID: 21634429]
    MDA-MB-231 IC50
    0.017 3
    Compound: Bortezomib
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    HEK293 IC50
    9.7 1
    Compound: Bortezomib
    Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control
    Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control
    		10.1039/C2MD20060K
    PC-3 GI50
    2.63 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human PC3 cells
    Growth inhibition of human PC3 cells
    		[PMID: 24946214]
    MDA-MB-231 IC50
    16.65 1
    Compound: PS-341
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    MDA-MB-231 IC50
    3.125 3
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    PBMC IC50
    2.7 1
    Compound: 1
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay
    		[PMID: 31283222]
    HET-1A IC50
    25.6 1
    Compound: PS-341
    Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    MDA-MB-231 IC50
    6.5 1
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    HL-60 ED50
    0.0025 3
    Compound: Bortezomib
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay
    		[PMID: 21973101]
    HL-60 ED50
    2.5 1
    Compound: bortezomib
    Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins
    Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins
    		[PMID: 19422206]
    MGC-803 IC50
    0.008 3
    Compound: Bortezomib
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    A549 GI50
    3.09 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human A549/ATCC cells
    Growth inhibition of human A549/ATCC cells
    		[PMID: 24946214]
    HL-60 IC50
    3.2 1
    Compound: Bortezomib
    Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    MGC-803 IC50
    5.782 1
    Compound: PS-341
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HL-60 IC50
    0.008 3
    Compound: Bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    MKN-45 IC50
    7.15 1
    Compound: PS-341
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HL-60 IC50
    3.2 1
    Compound: Bortezomib
    Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    HT-29 IC50
    3.2 1
    Compound: Btz
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    MM1.S IC50
    0.0026 3
    Compound: Bortezomib
    Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    		[PMID: 34969245]
    HL-60 IC50
    3.5 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HL-60 IC50
    3.5 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    RPMI-8226 IC50
    3.88 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay
    Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    HL-60 IC50
    5.5 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    MM1.S IC50
    0.0032 3
    Compound: Bortezomib
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    		[PMID: 36512676]
    Calu-6 IC50
    3.9 1
    Compound: Bortezomib
    Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay
    Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay
    		10.1039/C2MD20060K
    MM1.S IC50
    2.5 1
    Compound: BTZ
    Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    		[PMID: 34445874]
    HL-60 IC50
    6.9 1
    Compound: Bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    MOLT-4 EC50
    21 1
    Compound: 8
    Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate
    Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate
    		[PMID: 22503349]
    HL-60 IC50
    7.1 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    Multiple myeloma cancer stem cell IC50
    8.4 1
    Compound: BTZ
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    		[PMID: 30108696]
    NCI-H460 GI50
    4.47 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H460 cells
    Growth inhibition of human NCI-H460 cells
    		[PMID: 24946214]
    HL-60 IC50
    7.6 1
    Compound: PS-341
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    RPMI-8226 IC50
    4.7 1
    Compound: BTZ
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    		[PMID: 34445874]
    NCI-H23 IC50
    0.01 3
    Compound: Btz
    Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 30964987]
    HL-60(TB) GI50
    1.9 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HL-60(TB) cells
    Growth inhibition of human HL-60(TB) cells
    		[PMID: 24946214]
    HOP-62 GI50
    4.47 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HOP62 cells
    Growth inhibition of human HOP62 cells
    		[PMID: 24946214]
    NCI-H460 IC50
    115 1
    Compound: bortezomib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    HCT-116 IC50
    5 1
    Compound: bortezomib
    Inhibition of human HCT116 cell growth
    Inhibition of human HCT116 cell growth
    		[PMID: 24524217]
    NCI-H460 IC50
    780 1
    Compound: bortezomib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    HOP-92 GI50
    1 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HOP92 cells
    Growth inhibition of human HOP92 cells
    		[PMID: 24946214]
    NCI-H727 IC50
    0.025 3
    Compound: Btz
    Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 30964987]
    HT-29 ED50
    > 20 3
    Compound: Bortezomib
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    		[PMID: 21973101]
    HL-60 IC50
    5.5 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    U-266 IC50
    5.73 1
    Compound: Bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTS assay
    Cytotoxicity against human U266 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    NCI-H929 IC50
    10.85 1
    Compound: Bortezomib
    Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay
    Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay
    		[PMID: 24767818]
    HT-29 GI50
    0.95 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human HT-29 cells
    Growth inhibition of human HT-29 cells
    		[PMID: 24946214]
    MGC-803 IC50
    5.782 1
    Compound: PS-341
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    PBMC IC50
    < 35 1
    Compound: Bortezomib
    Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30365892]
    HT-29 IC50
    3.2 1
    Compound: Btz
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    PBMC IC50
    2.7 1
    Compound: 1
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay
    		[PMID: 31283222]
    ARH-77 IC50
    6.07 1
    Compound: Bortezomib
    Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay
    Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    HUVEC IC50
    11.2 1
    Compound: PS-341
    Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    PC-3 GI50
    0.04 3
    Compound: Bortezomib
    Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    SW480 IC50
    6.1 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    PC-3 IC50
    7 1
    Compound: bortezomib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    HCT-116 IC50
    0.01 3
    Compound: bortezomib
    Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay
    		[PMID: 23547757]
    PC-3 IC50
    8.3 1
    Compound: bortezomib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HCT-116 IC50
    0.001 3
    Compound: Bortezomib
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    MDA-MB-231 IC50
    6.5 1
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    RAW264.7 IC50
    0.03 3
    Compound: Bortezomib
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay
    		[PMID: 32738985]
    A549 IC50
    6.7 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    RKO IC50
    20.8 1
    Compound: Bortezomib
    Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    RPMI-8226 IC50
    0.0045 3
    Compound: Bortezomib
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    		[PMID: 34969245]
    RPMI-8226 IC50
    6.7 1
    Compound: Bortezomib
    Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay
    Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    HeLa GI50
    168.1 3
    Compound: BTZ; Product S4
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32031798]
    RPMI-8226 IC50
    0.0056 3
    Compound: Bortezomib
    Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    		[PMID: 36512676]
    5TGM1 IC50
    6.78 1
    Compound: PS-341, Bortezomib
    Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay
    Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay
    		[PMID: 24119559]
    HeLa IC50
    0.02 3
    Compound: PS-341
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19428245]
    HeLa IC50
    20 1
    Compound: Btz
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    RPMI-8226 IC50
    0.0064 3
    Compound: BTZ
    Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay
    Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay
    		[PMID: 34445874]
    HL-60 IC50
    6.9 1
    Compound: Bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    RPMI-8226 IC50
    1.43 1
    Compound: PS-341
    Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    PC-3 IC50
    7 1
    Compound: bortezomib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    HeLa IC50
    92 1
    Compound: bortezomib
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    RPMI-8226 IC50
    11.2 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    HeLa IC50
    > 200 1
    Compound: Btz
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    HL-60 IC50
    7.1 1
    Compound: bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    RPMI-8226 IC50
    3.88 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay
    Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    HepG2 EC50
    0.01 3
    Compound: Bortezomib
    Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay
    Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 29800827]
    MKN-45 IC50
    7.15 1
    Compound: PS-341
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    RPMI-8226 IC50
    4.7 1
    Compound: BTZ
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    		[PMID: 34445874]
    HepG2 EC50
    0.013 3
    Compound: BTZ
    Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay
    Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay
    		[PMID: 36608337]
    HepG2 IC50
    7.5 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    RPMI-8226 IC50
    6.7 1
    Compound: Bortezomib
    Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay
    Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    HepG2 GI50
    100.6 3
    Compound: BTZ; Product S4
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32031798]
    HL-60 IC50
    7.6 1
    Compound: PS-341
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    RPMI-8226 IC50
    7.96 1
    Compound: Bortezomib
    Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay
    Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay
    		[PMID: 24767818]
    RPMI-8226 IC50
    7.96 1
    Compound: Bortezomib
    Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay
    Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay
    		[PMID: 24767818]
    HepG2 IC50
    1.61 1
    Compound: PS-341
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    RPMI-8226 IC50
    9.5 1
    Compound: PS-341, Bortezomib
    Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay
    Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay
    		[PMID: 24119559]
    PC-3 IC50
    8.3 1
    Compound: bortezomib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HepG2 IC50
    25.2 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    SK-OV-3 IC50
    1.62 1
    Compound: PS-341
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    HepG2 IC50
    37.5 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    Multiple myeloma cancer stem cell IC50
    8.4 1
    Compound: BTZ
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    		[PMID: 30108696]
    U-266 IC50
    8.8 1
    Compound: bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    SK-OV-3 IC50
    12.9 1
    Compound: Bortezomib
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay
    		[PMID: 29767973]
    HepG2 IC50
    7.5 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    SK-OV-3 IC50
    130 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    RPMI-8226 IC50
    9.5 1
    Compound: PS-341, Bortezomib
    Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay
    Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay
    		[PMID: 24119559]
    SK-OV-3 IC50
    151 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    ARH-77 IC50
    9.57 1
    Compound: Bortezomib
    Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    SK-OV-3 IC50
    66.8 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    Hs-578T GI50
    1.02 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human Hs 578T cells
    Growth inhibition of human Hs 578T cells
    		[PMID: 24946214]
    HEK293 IC50
    9.7 1
    Compound: Bortezomib
    Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control
    Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control
    		10.1039/C2MD20060K
    HEK293 IC50
    10 1
    Compound: 1, bortezomib
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay
    Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay
    		[PMID: 20875739]
    SW1990 IC50
    79.06 1
    Compound: PS-341
    Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    IGROV-1 GI50
    2.24 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human IGROV1 cells
    Growth inhibition of human IGROV1 cells
    		[PMID: 24946214]
    SW480 IC50
    12.3 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HEK293 IC50
    14 3
    Compound: Bortezomib
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition
    Cytotoxicity against human HEK293 cells assessed as cell growth inhibition
    		[PMID: 33333398]
    SW480 IC50
    50 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    NCI-H929 IC50
    10.85 1
    Compound: Bortezomib
    Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay
    Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay
    		[PMID: 24767818]
    CCRF-CEM IC50
    11 1
    Compound: Bortezomib
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    SW480 IC50
    6.1 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    K562 GI50
    0.007 3
    Compound: Bortezomib
    Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    TOV21G IC50
    16.7 1
    Compound: Bortezomib
    Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    HUVEC IC50
    11.2 1
    Compound: PS-341
    Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    K562 GI50
    1.17 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human K562 cells
    Growth inhibition of human K562 cells
    		[PMID: 24946214]
    RPMI-8226 IC50
    11.2 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    U-266 GI50
    0.001 3
    Compound: Bortezomib
    Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    KB IC50
    59.5 1
    Compound: bortezomib
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    U-266 IC50
    11.63 1
    Compound: Bortezomib
    Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    U-266 IC50
    11.63 1
    Compound: Bortezomib
    Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    U-266 IC50
    12.2 1
    Compound: Bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    KM12 GI50
    1.7 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human KM12 cells
    Growth inhibition of human KM12 cells
    		[PMID: 24946214]
    BXPC-3 IC50
    11.8 1
    Compound: Bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    U-266 IC50
    12.5 1
    Compound: PS-341
    Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HEK-293T IC50
    12 1
    Compound: BTZ
    Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay
    Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay
    		[PMID: 28191850]
    U-266 IC50
    12.2 1
    Compound: Bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    U-266 IC50
    2.45 1
    Compound: bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    U-266 IC50
    5.73 1
    Compound: Bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTS assay
    Cytotoxicity against human U266 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    SW480 IC50
    12.3 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    U-266 IC50
    8.8 1
    Compound: bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    U-266 IC50
    12.5 1
    Compound: PS-341
    Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    WM 266-4 IC50
    0.035 3
    Compound: Bortezomib, Velcade, PS-341
    Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay
    Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay
    		[PMID: 22206869]
    GES1 IC50
    12.6 1
    Compound: PS-341
    Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    SK-OV-3 IC50
    12.9 1
    Compound: Bortezomib
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay
    		[PMID: 29767973]
    HEK293 IC50
    0.014 3
    Compound: PS-341
    Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay
    Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay
    		[PMID: 21044847]
    SK-OV-3 GI50
    13.8 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SKOV3 cells
    Growth inhibition of human SKOV3 cells
    		[PMID: 24946214]
    A549 IC50
    13.9 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HeLa GI50
    168.1 3
    Compound: BTZ; Product S4
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32031798]
    BXPC-3 IC50
    16.2 1
    Compound: bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    KM3/BTZ IC50
    226 1
    Compound: PS-341
    Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HeLa IC50
    0.02 3
    Compound: PS-341
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19428245]
    L02 IC50
    55.5 1
    Compound: PS-341
    Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    MDA-MB-231 IC50
    16.65 1
    Compound: PS-341
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    TOV21G IC50
    16.7 1
    Compound: Bortezomib
    Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    LOX IMVI GI50
    0.78 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human LOXIMVI cells
    Growth inhibition of human LOXIMVI cells
    		[PMID: 24946214]
    M14 GI50
    0.93 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human M14 cells
    Growth inhibition of human M14 cells
    		[PMID: 24946214]
    HepG2 EC50
    0.01 3
    Compound: Bortezomib
    Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay
    Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay
    		[PMID: 29800827]
    MCF7 GI50
    0.55 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MCF7 cells
    Growth inhibition of human MCF7 cells
    		[PMID: 24946214]
    HepG2 EC50
    0.013 3
    Compound: BTZ
    Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay
    Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay
    		[PMID: 36608337]
    HepG2 GI50
    100.6 3
    Compound: BTZ; Product S4
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32031798]
    MCF7 IC50
    0.025 3
    Compound: Bz
    Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
    Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
    		[PMID: 28557430]
    BXPC-3 IC50
    19.4 1
    Compound: bortezomib
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    MCF7 IC50
    18.37 3
    Compound: Bortezomib
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    HeLa IC50
    20 1
    Compound: Btz
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    HL-60 ED50
    0.0025 3
    Compound: Bortezomib
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay
    		[PMID: 21973101]
    MDA-MB-231 GI50
    1.26 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MDA-MB-231 cells
    Growth inhibition of human MDA-MB-231 cells
    		[PMID: 24946214]
    MDA-MB-231 IC50
    0.003 3
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    HL-60 IC50
    0.008 3
    Compound: Bortezomib
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    RKO IC50
    20.8 1
    Compound: Bortezomib
    Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    MDA-MB-231 IC50
    0.017 3
    Compound: Bortezomib
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    MOLT-4 EC50
    21 1
    Compound: 8
    Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate
    Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate
    		[PMID: 22503349]
    MDA-MB-231 IC50
    0.46 3
    Compound: Bortezomib
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    MOLT-4 EC50
    21 1
    Compound: 1, bortezomib
    Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells
    Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells
    		[PMID: 18247547]
    MDA-MB-231 IC50
    16.65 1
    Compound: PS-341
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    MDA-MB-231 IC50
    3.125 3
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    HT-29 ED50
    >20 3
    Compound: Bortezomib
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
    		[PMID: 21973101]
    BEL-7404 tumor cell line IC50
    25.04 1
    Compound: PS-341
    Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    MDA-MB-231 IC50
    6.5 1
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    HepG2 IC50
    25.2 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    MDA-MB-435 GI50
    0.44 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MDA-MB-435 cells
    Growth inhibition of human MDA-MB-435 cells
    		[PMID: 24946214]
    MDA-MB-468 GI50
    1.48 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MDA-MB-468 cells
    Growth inhibition of human MDA-MB-468 cells
    		[PMID: 24946214]
    HET-1A IC50
    25.6 1
    Compound: PS-341
    Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    HCT-116 IC50
    27 1
    Compound: Bortezomib
    Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    HEK293 IC50
    27 1
    Compound: 1a, Bortezomib
    Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader
    Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader
    		[PMID: 21634429]
    MGC-803 IC50
    0.008 3
    Compound: Bortezomib
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    MGC-803 IC50
    5.782 1
    Compound: PS-341
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    A-431 IC50
    28.2 1
    Compound: Bortezomib
    Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    MKN-45 IC50
    7.15 1
    Compound: PS-341
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    A2780 IC50
    28.9 1
    Compound: Bortezomib
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    MM1.S EC50
    0.002 3
    Compound: BTZ
    Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay
    Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay
    		[PMID: 36608337]
    K562 GI50
    0.007 3
    Compound: Bortezomib
    Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    HepG2 IC50
    37.5 1
    Compound: bortezomib
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    MM1.S IC50
    0.0026 3
    Compound: Bortezomib
    Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    		[PMID: 34969245]
    MM1.S IC50
    0.0032 3
    Compound: Bortezomib
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    		[PMID: 36512676]
    SW480 IC50
    50 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    L02 IC50
    55.5 1
    Compound: PS-341
    Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    MM1.S IC50
    2.5 1
    Compound: BTZ
    Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    		[PMID: 34445874]
    KB IC50
    59.5 1
    Compound: bortezomib
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    Cytotoxicity against human KB cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    MOLT-4 EC50
    21 1
    Compound: 1, bortezomib
    Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells
    Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells
    		[PMID: 18247547]
    MOLT-4 EC50
    21 1
    Compound: 8
    Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate
    Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate
    		[PMID: 22503349]
    MCF7 IC50
    0.025 3
    Compound: Bz
    Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
    Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
    		[PMID: 28557430]
    MCF7 IC50
    18.37 3
    Compound: Bortezomib
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    MOLT-4 GI50
    0.51 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MOLT4 cells
    Growth inhibition of human MOLT4 cells
    		[PMID: 24946214]
    Malme-3M GI50
    0.45 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human MALME-3M cells
    Growth inhibition of human MALME-3M cells
    		[PMID: 24946214]
    SK-OV-3 IC50
    66.8 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    MDA-MB-231 IC50
    3.125 3
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 29426629]
    MDA-MB-231 IC50
    0.003 3
    Compound: Bortezomib
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
    		[PMID: 33139111]
    MDA-MB-231 IC50
    0.017 3
    Compound: Bortezomib
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    Multiple myeloma cancer stem cell IC50
    8.4 1
    Compound: BTZ
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay
    		[PMID: 30108696]
    MDA-MB-231 IC50
    0.46 3
    Compound: Bortezomib
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    SW1990 IC50
    79.06 1
    Compound: PS-341
    Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    NCI-H226 GI50
    0.46 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H226 cells
    Growth inhibition of human NCI-H226 cells
    		[PMID: 24946214]
    NCI-H23 GI50
    1 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H23 cells
    Growth inhibition of human NCI-H23 cells
    		[PMID: 24946214]
    RPMI-8226 IC50
    80 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay
    		[PMID: 38381886]
    A549 IC50
    92 1
    Compound: BTZ
    Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay
    Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay
    		[PMID: 28191850]
    NCI-H23 IC50
    0.01 3
    Compound: Btz
    Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 30964987]
    NCI-H322M GI50
    17.8 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H322M cells
    Growth inhibition of human NCI-H322M cells
    		[PMID: 24946214]
    HeLa IC50
    92 1
    Compound: bortezomib
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    NCI-H460 GI50
    4.47 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H460 cells
    Growth inhibition of human NCI-H460 cells
    		[PMID: 24946214]
    MGC-803 IC50
    0.008 3
    Compound: Bortezomib
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 28634039]
    MM1.S EC50
    0.002 3
    Compound: BTZ
    Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay
    Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay
    		[PMID: 36608337]
    NCI-H460 IC50
    115 1
    Compound: bortezomib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    MM1.S IC50
    0.0026 3
    Compound: Bortezomib
    Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    		[PMID: 34969245]
    NCI-H460 IC50
    780 1
    Compound: bortezomib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    MM1.S IC50
    0.0032 3
    Compound: Bortezomib
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    		[PMID: 36512676]
    NCI-H522 GI50
    1.44 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-H522 cells
    Growth inhibition of human NCI-H522 cells
    		[PMID: 24946214]
    NCI-H727 IC50
    0.025 3
    Compound: Btz
    Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 30964987]
    NCI-H460 IC50
    115 1
    Compound: bortezomib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    SK-OV-3 IC50
    130 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    SK-OV-3 IC50
    151 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    KM3/BTZ IC50
    226 1
    Compound: PS-341
    Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    NCI-H23 IC50
    0.01 3
    Compound: Btz
    Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 30964987]
    A549 IC50
    255 1
    Compound: bortezomib
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    NCI-H727 IC50
    0.025 3
    Compound: Btz
    Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 30964987]
    HEK293 CC50
    347 1
    Compound: 1a, Bortezomib
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
    		[PMID: 21634429]
    PC-3 GI50
    0.04 3
    Compound: Bortezomib
    Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    RAW264.7 IC50
    0.03 3
    Compound: Bortezomib
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay
    		[PMID: 32738985]
    RPMI-8226 EC50
    0.004 3
    Compound: BTZ
    Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay
    Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay
    		[PMID: 36608337]
    NCI-H929 IC50
    10.85 1
    Compound: Bortezomib
    Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay
    Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay
    		[PMID: 24767818]
    RPMI-8226 IC50
    0.0045 3
    Compound: Bortezomib
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    		[PMID: 34969245]
    RPMI-8226 IC50
    0.0056 3
    Compound: Bortezomib
    Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    		[PMID: 36512676]
    NCI/ADR-RES GI50
    12.3 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human NCI-ADR-RES cells
    Growth inhibition of human NCI-ADR-RES cells
    		[PMID: 24946214]
    RPMI-8226 IC50
    0.0064 3
    Compound: BTZ
    Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay
    Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay
    		[PMID: 34445874]
    RPMI-8226 IC50
    0.0088 3
    Compound: 3
    Cytotoxicity against human RPMI8226 cells
    Cytotoxicity against human RPMI8226 cells
    		[PMID: 20727746]
    OVCAR-3 GI50
    0.54 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human OVCAR3 cells
    Growth inhibition of human OVCAR3 cells
    		[PMID: 24946214]
    NCI-H460 IC50
    780 1
    Compound: bortezomib
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    Cytotoxicity against human H460 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    OVCAR-4 GI50
    1.95 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human OVCAR4 cells
    Growth inhibition of human OVCAR4 cells
    		[PMID: 24946214]
    RPMI-8226 IC50
    5.24 3
    Compound: Bortezomib
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    OVCAR-5 GI50
    1.55 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human OVCAR5 cells
    Growth inhibition of human OVCAR5 cells
    		[PMID: 24946214]
    OVCAR-8 GI50
    2.63 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human OVCAR8 cells
    Growth inhibition of human OVCAR8 cells
    		[PMID: 24946214]
    BGC-823 IC50
    880 1
    Compound: bortezomib
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    A549 IC50
    2135.73 1
    Compound: PS-341
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    PBMC IC50
    2.7 1
    Compound: 1
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay
    Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay
    		[PMID: 31283222]
    PBMC IC50
    < 35 1
    Compound: Bortezomib
    Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30365892]
    BGC-823 IC50
    2890 1
    Compound: Bortezomib
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    PC-3 GI50
    0.04 3
    Compound: Bortezomib
    Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay
    		[PMID: 30802730]
    U-266 GI50
    0.001 3
    Compound: Bortezomib
    Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    PC-3 GI50
    2.63 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human PC3 cells
    Growth inhibition of human PC3 cells
    		[PMID: 24946214]
    PC-3 IC50
    7 1
    Compound: bortezomib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    PBMC IC50
    <35 1
    Compound: Bortezomib
    Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay
    Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay
    		[PMID: 30365892]
    PC-3 IC50
    8.3 1
    Compound: bortezomib
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    HeLa IC50
    >200 1
    Compound: Btz
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 35059132]
    WM 266-4 IC50
    0.035 3
    Compound: Bortezomib, Velcade, PS-341
    Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay
    Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay
    		[PMID: 22206869]
    RAW264.7 IC50
    0.03 3
    Compound: Bortezomib
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay
    Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay
    		[PMID: 32738985]
    RKO IC50
    20.8 1
    Compound: Bortezomib
    Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    RPMI-8226 EC50
    0.004 3
    Compound: BTZ
    Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay
    Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay
    		[PMID: 36608337]
    RPMI-8226 GI50
    0.23 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human RPMI8226 cells
    Growth inhibition of human RPMI8226 cells
    		[PMID: 24946214]
    RPMI-8226 IC50
    0.0045 3
    Compound: Bortezomib
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay
    		[PMID: 34969245]
    RPMI-8226 IC50
    0.0056 3
    Compound: Bortezomib
    Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay
    		[PMID: 36512676]
    RPMI-8226 IC50
    0.0064 3
    Compound: BTZ
    Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay
    Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay
    		[PMID: 34445874]
    RPMI-8226 IC50
    0.0088 3
    Compound: 3
    Cytotoxicity against human RPMI8226 cells
    Cytotoxicity against human RPMI8226 cells
    		[PMID: 20727746]
    RPMI-8226 IC50
    1.43 1
    Compound: PS-341
    Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    RPMI-8226 IC50
    11.2 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    RPMI-8226 IC50
    3.88 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay
    Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    RPMI-8226 IC50
    4.7 1
    Compound: BTZ
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
    		[PMID: 34445874]
    RPMI-8226 IC50
    5.24 3
    Compound: Bortezomib
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    RPMI-8226 IC50
    6.7 1
    Compound: Bortezomib
    Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay
    Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay
    		[PMID: 28182990]
    RPMI-8226 IC50
    7.96 1
    Compound: Bortezomib
    Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay
    Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay
    		[PMID: 24767818]
    RPMI-8226 IC50
    80 1
    Compound: Bortezomib
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay
    Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay
    		[PMID: 38381886]
    RPMI-8226 IC50
    9.5 1
    Compound: PS-341, Bortezomib
    Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay
    Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay
    		[PMID: 24119559]
    RXF 393 GI50
    0.71 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human RXF393 cells
    Growth inhibition of human RXF393 cells
    		[PMID: 24946214]
    SF-268 GI50
    1.17 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SF268 cells
    Growth inhibition of human SF268 cells
    		[PMID: 24946214]
    SF-295 GI50
    1.7 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SF295 cells
    Growth inhibition of human SF295 cells
    		[PMID: 24946214]
    SF-539 GI50
    0.59 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SF539 cells
    Growth inhibition of human SF539 cells
    		[PMID: 24946214]
    SK-MEL-2 GI50
    1.07 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SK-MEL-2 cells
    Growth inhibition of human SK-MEL-2 cells
    		[PMID: 24946214]
    SK-MEL-28 GI50
    0.46 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SK-MEL-28 cells
    Growth inhibition of human SK-MEL-28 cells
    		[PMID: 24946214]
    SK-MEL-5 GI50
    0.68 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SK-MEL-5 cells
    Growth inhibition of human SK-MEL-5 cells
    		[PMID: 24946214]
    SK-OV-3 GI50
    13.8 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SKOV3 cells
    Growth inhibition of human SKOV3 cells
    		[PMID: 24946214]
    SK-OV-3 IC50
    1.62 1
    Compound: PS-341
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    SK-OV-3 IC50
    12.9 1
    Compound: Bortezomib
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay
    Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay
    		[PMID: 29767973]
    SK-OV-3 IC50
    130 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    SK-OV-3 IC50
    151 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    SK-OV-3 IC50
    66.8 1
    Compound: bortezomib
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    SN12C GI50
    1.1 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SN12C cells
    Growth inhibition of human SN12C cells
    		[PMID: 24946214]
    SNB-19 GI50
    2.04 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SNB19 cells
    Growth inhibition of human SNB19 cells
    		[PMID: 24946214]
    SNB-75 GI50
    2.04 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SNB75 cells
    Growth inhibition of human SNB75 cells
    		[PMID: 24946214]
    SR GI50
    0.85 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SR cells
    Growth inhibition of human SR cells
    		[PMID: 24946214]
    SW-620 GI50
    0.55 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human SW620 cells
    Growth inhibition of human SW620 cells
    		[PMID: 24946214]
    SW1990 IC50
    79.06 1
    Compound: PS-341
    Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay
    		[PMID: 27769033]
    SW480 IC50
    12.3 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 21077681]
    SW480 IC50
    50 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    SW480 IC50
    6.1 1
    Compound: bortezomib
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    T47D GI50
    0.6 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human T47D cells
    Growth inhibition of human T47D cells
    		[PMID: 24946214]
    THP-1 IC50
    6.28 1
    Compound: BTZ
    Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37979441]
    TK-10 GI50
    1 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human TK10 cells
    Growth inhibition of human TK10 cells
    		[PMID: 24946214]
    TOV21G IC50
    16.7 1
    Compound: Bortezomib
    Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay
    Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay
    		[PMID: 26231162]
    U-251 GI50
    1.55 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human U251 cells
    Growth inhibition of human U251 cells
    		[PMID: 24946214]
    U-266 GI50
    0.001 3
    Compound: Bortezomib
    Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay
    Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay
    		[PMID: 28441582]
    U-266 IC50
    11.63 1
    Compound: Bortezomib
    Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
    		[PMID: 29934218]
    U-266 IC50
    12.2 1
    Compound: Bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 19747832]
    U-266 IC50
    12.5 1
    Compound: PS-341
    Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
    Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay
    		[PMID: 32267687]
    U-266 IC50
    2.45 1
    Compound: bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 19537716]
    U-266 IC50
    5.73 1
    Compound: Bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTS assay
    Cytotoxicity against human U266 cells after 72 hrs by MTS assay
    		[PMID: 26965867]
    U-266 IC50
    8.8 1
    Compound: bortezomib
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    Cytotoxicity against human U266 cells after 72 hrs by MTT assay
    		[PMID: 20158184]
    U-87MG ATCC IC50
    7.86 3
    Compound: Bortezomib
    Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay
    		[PMID: 38381886]
    UACC-257 GI50
    0.59 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human UACC257 cells
    Growth inhibition of human UACC257 cells
    		[PMID: 24946214]
    UACC-62 GI50
    0.91 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human UACC62 cells
    Growth inhibition of human UACC62 cells
    		[PMID: 24946214]
    UO-31 GI50
    1.05 1
    Compound: Bortezomib, Velcade
    Growth inhibition of human UO31 cells
    Growth inhibition of human UO31 cells
    		[PMID: 24946214]
    WM 266-4 IC50
    0.035 3
    Compound: Bortezomib, Velcade, PS-341
    Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay
    Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay
    		[PMID: 22206869]
    In Vitro

    Bortezomib (PS-341) (100 nM; 8 hours) results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1[1].
    Bortezomib (PS-341) (5-100 nM; 20 hours) induces apoptosis in mantle-cell lymphoma (MCL) cell lines[3].
    Bortezomib (PS-341) (20 nM; 1-14 hours) induces Noxa up-regulation in both MCL cell lines[3].
    The IC50 of Bortezomib (PS-341) is found to be 2.46 nM for 26S proteasome in the B16F10 cells[4].
    Bortezomib (PS-341) suppresses several anti-apoptotic proteins (e.g., Bcl-XL, Bcl-2, and STAT-3)[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Bortezomib Related Antibodies

    Cell Cycle Analysis[1]

    Cell Line: PC-3 cells
    Concentration: 100 nM
    Incubation Time: 8 hours
    Result: Resulted in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1.

    Apoptosis Analysis[3]

    Cell Line: JVM-2, Granta-519, Jeko, REC-1 cells (MCL cell lines)
    Concentration: 5-100 nM
    Incubation Time: 20 hours
    Result: The median LD50 for these MCL cell lines was 31 nM (range, 18.2-60.1 nM).

    Western Blot Analysis[3]

    Cell Line: wtp53 (Granta-519), mutp53 (Jeko) cells
    Concentration: 20 nM
    Incubation Time: 1, 2, 4, 6, 14 hours
    Result: Noxa up-regulation was detected between 2 to 4 hours after bortezomib (PS-341).
    In Vivo

    Bortezomib (PS-341) (0.3-1 mg/kg; i.v.; once weekly for 4 weeks) inhibits PC-3 Tumor Growth in Nude Mice[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male nude mice (xenograft tumor model bearing PC-3 cells)[1]
    Dosage: 0.3, 1 mg/kg
    Administration: Intravenous injection; once weekly for 4 weeks
    Result: Resulted in a significant decrease in tumor growth ~60% at dose of 1 mg/kg.
    Clinical Trial
    Molecular Weight

    384.24

    Formula

    C19H25BN4O4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C)

    DMSO : 50 mg/mL (130.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.6025 mL 13.0127 mL 26.0254 mL
    5 mM 0.5205 mL 2.6025 mL 5.2051 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

      This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% EtOH    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

      This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.97%

    SDS (557 KB)

    COA (251 KB) HNMR (198 KB) LCMS (349 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / Ethanol 1 mM 2.6025 mL 13.0127 mL 26.0254 mL 65.0635 mL
    5 mM 0.5205 mL 2.6025 mL 5.2051 mL 13.0127 mL
    10 mM 0.2603 mL 1.3013 mL 2.6025 mL 6.5064 mL
    15 mM 0.1735 mL 0.8675 mL 1.7350 mL 4.3376 mL
    20 mM 0.1301 mL 0.6506 mL 1.3013 mL 3.2532 mL
    25 mM 0.1041 mL 0.5205 mL 1.0410 mL 2.6025 mL
    30 mM 0.0868 mL 0.4338 mL 0.8675 mL 2.1688 mL
    40 mM 0.0651 mL 0.3253 mL 0.6506 mL 1.6266 mL
    50 mM 0.0521 mL 0.2603 mL 0.5205 mL 1.3013 mL
    60 mM 0.0434 mL 0.2169 mL 0.4338 mL 1.0844 mL
    80 mM 0.0325 mL 0.1627 mL 0.3253 mL 0.8133 mL
    100 mM 0.0260 mL 0.1301 mL 0.2603 mL 0.6506 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Bortezomib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Bortezomib179324-69-7PS-341 LDP-341 NSC 681239PS341PS 341LDP341LDP 341LDP-341NSC681239NSC 681239NSC-681239ProteasomeNF-κBApoptosisAutophagyTREM receptorNuclear factor-κBNuclear factor-kappaBTriggering receptors expressed on myeloid cellsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Bortezomib
    Cat. No.:
    HY-10227
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (557 KB) Français - FR (557 KB) Deutsch - DE (557 KB) Norwegian - NO (557 KB) Español - ES (557 KB) Swedish - SV (557 KB) Italian - IT (557 KB) Korean - KR (557 KB) Portuguese - PT (557 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.